John B. Cheng

2.4k total citations
59 papers, 2.0k citations indexed

About

John B. Cheng is a scholar working on Molecular Biology, Physiology and Pharmacology. According to data from OpenAlex, John B. Cheng has authored 59 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 29 papers in Physiology and 12 papers in Pharmacology. Recurrent topics in John B. Cheng's work include Asthma and respiratory diseases (22 papers), Receptor Mechanisms and Signaling (14 papers) and Phosphodiesterase function and regulation (14 papers). John B. Cheng is often cited by papers focused on Asthma and respiratory diseases (22 papers), Receptor Mechanisms and Signaling (14 papers) and Phosphodiesterase function and regulation (14 papers). John B. Cheng collaborates with scholars based in United States, Japan and Netherlands. John B. Cheng's co-authors include Douglas A. Fisher, James F. Smith, Robert G. Townley, J. W. Watson, Shoji Shibata, Alan Goldfien, James M. Roberts, Victoria L. Cohan, Susan Tofte and Jon M. Hanifin and has published in prestigious journals such as Journal of Biological Chemistry, Gastroenterology and Gut.

In The Last Decade

John B. Cheng

58 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John B. Cheng United States 23 1.1k 506 413 334 242 59 2.0k
Yves Boie Canada 20 1.0k 0.9× 553 1.1× 904 2.2× 336 1.0× 127 0.5× 24 2.3k
Jianguo Jin United States 27 1.0k 0.9× 184 0.4× 228 0.6× 337 1.0× 132 0.5× 49 3.5k
Kimihiko Sano Japan 24 1.3k 1.2× 231 0.5× 138 0.3× 341 1.0× 114 0.5× 60 2.7k
Leonard P. Adam United States 24 1.2k 1.1× 435 0.9× 145 0.4× 129 0.4× 128 0.5× 52 2.0k
Nancy Lewis Baenziger United States 19 753 0.7× 255 0.5× 411 1.0× 226 0.7× 42 0.2× 30 2.0k
Ruth R. Osborn United States 15 526 0.5× 743 1.5× 145 0.4× 362 1.1× 69 0.3× 30 1.5k
Yasushi Fujitani Japan 16 660 0.6× 864 1.7× 192 0.5× 387 1.2× 50 0.2× 21 1.6k
Iain Uings United Kingdom 21 484 0.4× 306 0.6× 111 0.3× 256 0.8× 91 0.4× 41 1.2k
Barrie Ashby United States 25 819 0.7× 252 0.5× 350 0.8× 135 0.4× 42 0.2× 47 1.9k
J A Lindgren Sweden 8 315 0.3× 513 1.0× 262 0.6× 373 1.1× 48 0.2× 8 1.3k

Countries citing papers authored by John B. Cheng

Since Specialization
Citations

This map shows the geographic impact of John B. Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John B. Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John B. Cheng more than expected).

Fields of papers citing papers by John B. Cheng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John B. Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John B. Cheng. The network helps show where John B. Cheng may publish in the future.

Co-authorship network of co-authors of John B. Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of John B. Cheng. A scholar is included among the top collaborators of John B. Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John B. Cheng. John B. Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhu, Ming, Susan Pleasic‐Williams, Tsung H. Lin, et al.. (2013). pSTAT3: a target biomarker to study the pharmacology of the anti-IL-21R antibody ATR-107 in human whole blood. Journal of Translational Medicine. 11(1). 65–65. 11 indexed citations
2.
Chambers, Robert, John B. Cheng, Douglas A. Fisher, et al.. (2005). A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function. Bioorganic & Medicinal Chemistry Letters. 16(3). 718–721. 4 indexed citations
3.
Kudlacz, Elizabeth M., et al.. (1999). Characterization of chemokine CCR3 agonist‐mediated eosinophil recruitment in the Brown‐Norway rat. British Journal of Pharmacology. 128(3). 788–794. 5 indexed citations
4.
Chambers, Robert, Anthony Marfat, John B. Cheng, et al.. (1999). Discovery of CP-199,330 and CP-199,331: Two potent and orally efficacious cysteinyl LT1 receptor antagonists devoid of liver toxicity. Bioorganic & Medicinal Chemistry Letters. 9(18). 2773–2778. 13 indexed citations
5.
Chambers, Robert, et al.. (1998). Development of 2,2-dimethylchromanol cysteinyl LT1 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 8(24). 3577–3582. 6 indexed citations
6.
Fisher, Douglas A., et al.. (1998). Isolation and Characterization of PDE9A, a Novel Human cGMP-specific Phosphodiesterase. Journal of Biological Chemistry. 273(25). 15559–15564. 287 indexed citations
7.
Chambers, Robert, et al.. (1998). Development of new chromanol antagonists of leukotriene D4. Bioorganic & Medicinal Chemistry Letters. 8(14). 1791–1796. 9 indexed citations
8.
Fisher, Douglas A., et al.. (1998). Isolation and Characterization of PDE8A, a Novel Human cAMP-Specific Phosphodiesterase. Biochemical and Biophysical Research Communications. 246(3). 570–577. 191 indexed citations
9.
Cheng, John B., J. W. Watson, Christopher J. Pazoles, et al.. (1997). The Phosphodiesterase Type 4 (PDE4) Inhibitor CP-80,633 Elevates Plasma Cyclic AMP Levels and Decreases Tumor Necrosis Factor-α (TNFα) Production in Mice: Effect of Adrenalectomy. Journal of Pharmacology and Experimental Therapeutics. 280(2). 621–626. 13 indexed citations
10.
Turner, Claudia R., Victoria L. Cohan, John B. Cheng, et al.. (1996). The in vivo pharmacology of CP-80, 633, a selective inhibitor of phosphodiesterase 4.. Journal of Pharmacology and Experimental Therapeutics. 278(3). 1349–1355. 22 indexed citations
11.
Hanifin, Jon M., Sai C. Chan, John B. Cheng, et al.. (1996). Type 4 Phosphodiesterase Inhibitors Have Clinical and In Vitro Anti-inflammatory Effects in Atopic Dermatitis. Journal of Investigative Dermatology. 107(1). 51–56. 188 indexed citations
12.
Cohan, Victoria L., Henry J. Showell, Christopher J. Pazoles, et al.. (1996). In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.. Journal of Pharmacology and Experimental Therapeutics. 278(3). 1356–1361. 49 indexed citations
13.
Pettipher, E. R., et al.. (1996). Regulation of tumour necrosis factor production by adrenal hormones in vivo: insights into the antiinflammatory activity of rolipram. British Journal of Pharmacology. 117(7). 1530–1534. 43 indexed citations
14.
Koch, Kevin M., Lawrence S. Melvin, Lawrence A. Reiter, et al.. (1994). (+)-1-(3S,4R)-[3-(4-Phenylbenzyl)-4- hydroxychroman-7-yl]cyclopentane Carboxylic Acid, a Highly Potent, Selective Leukotriene B4 Antagonist with Oral Activity in the Murine Collagen-Induced Arthritis Model. Journal of Medicinal Chemistry. 37(20). 3197–3199. 48 indexed citations
15.
Cheng, John B., et al.. (1993). Antigen-mediated pulmonary eosinophilia in immunoglobulin G1-sensitized guinea pigs: eosinophil peroxidase as a simple specific marker for detecting eosinophils in bronchoalveolar lavage fluid.. Journal of Pharmacology and Experimental Therapeutics. 264(2). 922–929. 21 indexed citations
16.
17.
Cheng, John B., et al.. (1990). Evidence that peptidoleukotriene is a prerequisite for antigen-dependent thromboxane synthesis in IgG1-passively sensitized guinea pig lungs.. Journal of Pharmacology and Experimental Therapeutics. 255(2). 664–671. 6 indexed citations
18.
19.
Payne, Adrian N. & John B. Cheng. (1990). PMNs and airway inflammation/hyperreactivity. Inflammation Research. 29(3-4). 181–183. 3 indexed citations
20.
Cheng, John B.. (1986). LTC4 ‘receptor’: its demonstration using airway and non-airway tissues. Trends in Pharmacological Sciences. 7. 477–478. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yves Boie Breakdown of academic impact, for papers by Jianguo Jin Breakdown of academic impact, for papers by Kimihiko Sano Breakdown of academic impact, for papers by Leonard P. Adam Breakdown of academic impact, for papers by Nancy Lewis Baenziger Breakdown of academic impact, for papers by Ruth R. Osborn Breakdown of academic impact, for papers by Yasushi Fujitani Breakdown of academic impact, for papers by Iain Uings Breakdown of academic impact, for papers by Barrie Ashby Breakdown of academic impact, for papers by J A Lindgren
Rankless by CCL
2026